on ABIVAX (EPA:ABVX)
Abivax Reports Full Year 2025 Financial Results and Business Updates
Abivax, a biotechnology company, has released its financial results for 2025. Despite an increase in research and development expenses, mainly due to clinical trials for obefazimod in ulcerative colitis and Crohn’s disease, the company finished 2025 with €530.4 million in cash and a projected runway into Q4 2027.
In 2025, Abivax raised approximately €597.2 million through a public offering. The company's operating loss increased to €246.1 million, driven by higher general and administrative costs. This cost surge was primarily linked to rising personnel expenses.
The year marked a pivotal point for Abivax with strategic leadership appointments to prepare for potential commercialization of obefazimod. Notably, Michael Nesrallah was appointed Chief Commercial Officer to strengthen commercial capabilities ahead of obefazimod's anticipated market launch.
Looking forward, the company plans to announce Q1 2026 financial results in May and expects key clinical trial results for its ulcerative colitis treatment in late Q2 2026.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news